NSF Program Attempts To Address Concerns Of Peer Review Critics

For years, critics have argued that the National Science Foundation's system of grant review is not receptive to novel or unorthodox ideas. But NSF has not failed to take notice of this charge. In 1989, spurred by complaints about reviewer conservatism, NSF introduced a new type of award known as Small Grants for Exploratory Research (SGER). Although still not widely known today, these grants exist expressly for the purpose of supporting speculative research endeavors that might not otherwise r

Written byJeff Seiken
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In discussing the SGERs, Mc-Cullough is careful to point out that they are not a distinct program of their own, but rather "an alternative mechanism [for awarding research grants] that any program officer can use." The money for an SGER, which is nonrenewable and may not exceed $50,000, comes out of the budget of the program issuing it. Program officers in all 28 NSF divisions can award SGERs at their discretion, with the proviso that no more than 5 percent of a program's annual budget may be spent on these grants.

In keeping with the small-scale nature of the awards, the application process is simple and direct. Applications are limited to two to five pages in length--"back-of-the-envelope kinds of proposals," McCullough says. Although principal inves- tigators are required to submit brief bios, no more than five publications or research products may be cited. Proposals are subsequently evaluated by program officers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies